Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 203
- Registration Number
- NCT00166504
EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 367
- Registration Number
- NCT00166530
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2021-02-18
- Target Recruit Count
- 128
- Registration Number
- NCT00163150
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, Cedex 18, France
Comparative Atorvastatin Pleiotropic Effects
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2021-02-18
- Target Recruit Count
- 330
- Registration Number
- NCT00163202
- Locations
- 🇸🇰
Pfizer Investigational Site, Bratislava, Slovakia
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8600
- Registration Number
- NCT00159835
- Locations
Pfizer Investigational Site
Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2006-09-28
- Lead Sponsor
- Technische Universität Dresden
- Registration Number
- NCT00154024
- Locations
- 🇩🇪
Institute of Clinical Pharmacology, Medical Faculty, University of Technology, Dresden, Germany
Double Blind Atorvastatin Amlodipine Study
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2021-01-28
- Target Recruit Count
- 360
- Registration Number
- NCT00159718
- Locations
Pfizer Investigational Site
Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 190
- Registration Number
- NCT00157924
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2021-02-18
- Target Recruit Count
- 600
- Registration Number
- NCT00151502
- Locations
- 🇬🇧
Pfizer Investigational Site, Stirling, United Kingdom
Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2021-02-18
- Target Recruit Count
- 1100
- Registration Number
- NCT00150371
- Locations
- 🇨🇦
Pfizer Investigational Site, St. John's, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.